Teblik Drugs Profile
Key Indicators
- Authorised Capital ₹ 3.50 M
as on 12-12-2024
- Paid Up Capital ₹ 2.51 M
as on 12-12-2024
- Company Age 35 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.00 M
as on 12-12-2024
- Satisfied Charges ₹ 3.62 Cr
as on 12-12-2024
- Revenue 0.15%
(FY 2017)
- Profit 15.13%
(FY 2017)
- Ebitda 27.95%
(FY 2017)
- Net Worth 3.53%
(FY 2017)
- Total Assets 15.98%
(FY 2017)
About Teblik Drugs
The Corporate was formerly known as Teblik Drugs Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.50 M and a paid-up capital of Rs 2.51 M.
The company currently has active open charges totaling ₹5.00 M. The company has closed loans amounting to ₹3.62 Cr, as per Ministry of Corporate Affairs (MCA) records.
Soham Sharma, Shobhit Sharma, and Renu Sharma serve as directors at the Company.
- CIN/LLPIN
U24232MP1989PTC005061
- Company No.
005061
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Feb 1989
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Teblik Drugs Private Limited offer?
Teblik Drugs Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup, Plastic Containers & Bottles, Pharmaceutical Containers, Ayurvedic Herbal Syrups & Tonics, Herbal Cough Syrup, Injectable Products, Dry Injections, Antiseptic Gel, Lotion & Cream, Povidone Iodine Ointment.
Who are the key members and board of directors at Teblik Drugs?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shobhit Sharma  | Director | 28-Mar-2014 | Current |
| Soham Sharma | Director | 02-Feb-1989 | Current |
| Renu Sharma | Director | 28-Mar-2014 | Current |
Financial Performance of Teblik Drugs.
Teblik Drugs Private Limited, for the financial year ended 2017, experienced modest growth in revenue, with a 0.15% increase. The company also saw a substantial improvement in profitability, with a 15.13% increase in profit. The company's net worth moved up by a moderate rise of 3.53%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Teblik Drugs?
In 2017, Teblik Drugs had a promoter holding of 19.99% and a public holding of 80.01%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 31 May 2022 | ₹5.00 M | Open |
Others Creation Date: 23 Jun 2016 | ₹3.60 M | Satisfied |
Small Industries Development Bank Of India Creation Date: 29 Jun 2009 | ₹2.50 M | Satisfied |
How Many Employees Work at Teblik Drugs?
Teblik Drugs has a workforce of 16 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Teblik Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Teblik Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
